Jiangsu Hengrui Medicine advances dual therapies for lymphoma, obesity

Jiangsu Hengrui Medicine (SSE:600276) announced the conditional approval from the National Medical Products Administration for its innovative Class 1 drug, Zemexi Tositab (SHR2554), for adult patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) who have undergone at least one prior systemic therapy. This oral EZH2 inhibitor is the first self-developed EZH2 inhibitor in China. The cumulative R&D investment for SHR2554 to date is approximately RMB 213 million.

Separately, Jiangsu Hengrui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received marketing application acceptance for HRS9531 injection for long-term weight management in adults with obesity or overweight conditions. The Phase III clinical trial for HRS9531 injection met its primary and all key secondary endpoints, demonstrating significant weight reduction and good safety. The cumulative R&D investment for HRS9531 is approximately RMB 45,235 million.